Prothena Corp (PRTA)

$11.07 -0.09 (-0.81%)
Market Cap 600.74M
Revenue (ttm) 135.16M
Net Income (ttm) -122.31M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -90.49%
Debt to Equity Ratio 0.00
Volume 434,600
Avg Vol 632,960
Day's Range N/A - N/A
Shares Out 53.83M
Stochastic %K 65%
Beta -0.10
Analysts Sell
Price Target $20.33

Company Profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. Its product pipeline include Prasinezumab, an investigational humanized monoclonal antibody which is in phase 2b clinical trial, as well as phase 1 and 2 clinical trials for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antib...

Industry: Biotechnology
Sector: Healthcare
Phone: 353 1 236 2500
Fax: 353 1 902 3510
Address:
77 Sir John Rogerson’s Quay, Block C Grand Canal Docklands, Dublin, Ireland
AIIAAIIA_88
AIIAAIIA_88 Dec. 5 at 8:43 PM
$PRTA What is it with the short sellers and bears who cannot tolerate seeing this stock over $11 for a day??!! They will be kicking and crying soon enough. JMO
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Dec. 3 at 8:49 PM
https://stocktwits.com/news-articles/markets/equity/bristol-myers-stock-jumps-as-wall-street-backs-added-enrollment-in-alzheimer-s-trial/cLIXwRaRE1p This is with $PRTA drug candidate for AD. Incredible that the article does not mention $PRTA. But I know! This is why the stock is up almost 10% today.
1 · Reply
AIIAAIIA_88
AIIAAIIA_88 Dec. 3 at 2:42 PM
$PRTA Please be like CAPR soon. Very soon! 🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 2 at 7:45 PM
$PROP $PRTA $PSCE $PSCI $PSCT Undeniable Accuracy Cycle Trading Signal plugged into AI 🔥 lists 🔥 Math don't lie 🔥
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Dec. 1 at 2:52 PM
$PRTA The AD + PD winner, I am sure of. Everyone thought that this one was dead earlier this year. Not by a long shot, nope. It is still alive and kicking! You will see very soon. JMO
0 · Reply
JarvisFlow
JarvisFlow Dec. 1 at 1:17 PM
Citizens updates rating for Prothena Corp ( $PRTA ) to Market Outperform, target set at 11 → 19.
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Nov. 26 at 3:20 PM
$PRTA AD and PD are graveyards for drug candidates so far. So many Big Pharmas like NVO, JNJ, and a little biotechs like SAVA, AVXL, ALEC, ANVS, BIVI, CGTX are all failing or has failed. BMY still has PRTA’s AD drug candidate in ongoing P2 and P1, and Roche still has P3 for PRTA’s drug candidates for PD. Besides, the amyloid protein buildup is now proven to be associated with aging! For longevity, one wants to rid of the amyloids buildup! This December will be awesome! LFG!! 🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀
1 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 23 at 3:55 PM
$PROP $PRTA $PSCE $PSCI $PSCT 🔥
0 · Reply
buyandsold
buyandsold Nov. 22 at 2:38 AM
$PRTA this is 32% of my port, i would surely appreciate a $35 buyout on Monday
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Nov. 18 at 2:37 AM
$PRTA This biotech is already partnering with not one, not two, but three big pharma companies! BMY, NVO, RHHBY. Why chase others that keep promising partnerships that never materialize???? Beats me. LMAO
0 · Reply
Latest News on PRTA
Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025

Nov 19, 2025, 4:05 PM EST - 16 days ago

Prothena Announces Poster Presentation on its TDP-43 CYTOPE® Program at Neuroscience 2025

Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA

Nov 11, 2025, 9:00 AM EST - 24 days ago

Prothena Highlights Phase 2 Data for Coramitug (Formerly PRX004) Published in Circulation, Official Journal of AHA

Prothena Reports Third Quarter 2025 Financial Results and Business Highlights

Nov 6, 2025, 4:05 PM EST - 4 weeks ago

Prothena Reports Third Quarter 2025 Financial Results and Business Highlights

Prothena to Report Third Quarter 2025 Financial Results on November 6

Oct 30, 2025, 4:05 PM EDT - 5 weeks ago

Prothena to Report Third Quarter 2025 Financial Results on November 6

Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease

Oct 1, 2025, 4:45 PM EDT - 2 months ago

Prothena's Partner Bristol Myers Squibb Obtains Fast Track Designation from the U.S. FDA for BMS-986446 (PRX005), an Anti-MTBR-Tau-Targeting Antibody, for the Treatment of Alzheimer's Disease

Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference

Aug 28, 2025, 4:05 PM EDT - 3 months ago

Prothena to Participate in the Cantor Fitzgerald Global Healthcare Conference

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

Aug 27, 2025, 4:05 PM EDT - 3 months ago

Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Aug 6, 2025, 9:00 AM EDT - 4 months ago

Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy

Prothena Q2 Revenue Drops 97%

Aug 5, 2025, 1:07 PM EDT - 4 months ago

Prothena Q2 Revenue Drops 97%

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

Aug 4, 2025, 4:05 PM EDT - 4 months ago

Prothena Reports Second Quarter 2025 Financial Results and Business Highlights

Prothena to Report Second Quarter 2025 Financial Results on August 4

Jul 28, 2025, 4:05 PM EDT - 4 months ago

Prothena to Report Second Quarter 2025 Financial Results on August 4

Prothena Announces Corporate Restructuring

Jun 18, 2025, 4:05 PM EDT - 6 months ago

Prothena Announces Corporate Restructuring

Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Jun 16, 2025, 1:06 AM EDT - 6 months ago

Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Why Is Prothena Stock Trading Lower On Tuesday?

May 27, 2025, 7:43 AM EDT - 6 months ago

Why Is Prothena Stock Trading Lower On Tuesday?

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

May 23, 2025, 4:05 PM EDT - 7 months ago

Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint

Top 3 Health Care Stocks That Are Preparing To Pump This Quarter

May 9, 2025, 7:16 AM EDT - 7 months ago

Top 3 Health Care Stocks That Are Preparing To Pump This Quarter

RXST SRPT

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

May 8, 2025, 4:05 PM EDT - 7 months ago

Prothena Reports First Quarter 2025 Financial Results and Business Highlights

Prothena to Report First Quarter 2025 Financial Results on May 8

May 1, 2025, 4:05 PM EDT - 7 months ago

Prothena to Report First Quarter 2025 Financial Results on May 8

Prothena Corporation plc (PRTA) Q4 2024 Earnings Call Transcript

Feb 20, 2025, 8:45 PM EST - 10 months ago

Prothena Corporation plc (PRTA) Q4 2024 Earnings Call Transcript

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

Feb 20, 2025, 4:05 PM EST - 10 months ago

Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights

Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm

Feb 17, 2025, 6:10 PM EST - 10 months ago

Kuehn Law Encourages Investors of Prothena Corporation PLC to Contact Law Firm

Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Feb 13, 2025, 4:05 PM EST - 10 months ago

Prothena to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

Prothena Announces Board of Directors Update

Dec 30, 2024, 4:05 PM EST - 1 year ago

Prothena Announces Board of Directors Update

Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease

Dec 19, 2024, 1:05 AM EST - 1 year ago

Roche's Phase IIb Study of Prasinezumab Missed Primary Endpoint, But Suggests Possible Clinical Benefit in Early-Stage Parkinson's Disease

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Nov 12, 2024, 4:05 PM EST - 1 year ago

Prothena Reports Third Quarter 2024 Financial Results and Business Highlights

Prothena to Report Third Quarter 2024 Financial Results on November 12

Nov 5, 2024, 4:05 PM EST - 1 year ago

Prothena to Report Third Quarter 2024 Financial Results on November 12

Prothena Announces Leadership Team Updates

Sep 27, 2024, 4:05 PM EDT - 1 year ago

Prothena Announces Leadership Team Updates

Prothena to Participate in Upcoming Healthcare Conferences

Aug 29, 2024, 4:05 PM EDT - 1 year ago

Prothena to Participate in Upcoming Healthcare Conferences

Prothena Reports Second Quarter 2024 Financial Results and Business Highlights

Aug 8, 2024, 4:05 PM EDT - 1 year ago

Prothena Reports Second Quarter 2024 Financial Results and Business Highlights

Prothena to Report Second Quarter 2024 Financial Results on August 8

Aug 1, 2024, 4:05 PM EDT - 1 year ago

Prothena to Report Second Quarter 2024 Financial Results on August 8

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

May 28, 2024, 4:05 PM EDT - 1 year ago

Prothena Announces Bristol Myers Squibb Opt-in for Exclusive Global License for PRX019, the Second Program from Global Neuroscience Research and Development Collaboration

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

May 8, 2024, 4:05 PM EDT - 1 year ago

Prothena Reports First Quarter 2024 Financial Results and Business Highlights

Prothena to Report First Quarter 2024 Financial Results on May 8

May 1, 2024, 4:05 PM EDT - 1 year ago

Prothena to Report First Quarter 2024 Financial Results on May 8

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Apr 15, 2024, 4:05 PM EDT - 1 year ago

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma

Prothena Appoints David Ford to Newly Created Chief People Officer Position

Mar 4, 2024, 4:05 PM EST - 1 year ago

Prothena Appoints David Ford to Newly Created Chief People Officer Position

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

Feb 23, 2024, 12:31 PM EST - 1 year ago

Prothena: Alzheimer's Data Update In 2024 Could Move The Needle

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate

Feb 21, 2024, 4:05 PM EST - 1 year ago

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate

Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript

Feb 15, 2024, 11:53 PM EST - 1 year ago

Prothena Corporation plc (PRTA) Q4 2023 Earnings Call Transcript

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Feb 15, 2024, 4:05 PM EST - 1 year ago

Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights

Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

Feb 8, 2024, 4:05 PM EST - 1 year ago

Prothena to Report Fourth Quarter and Full Year 2023 Financial Results on February 15, 2024

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Jan 8, 2024, 8:30 AM EST - 2 years ago

Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Nov 2, 2023, 4:05 PM EDT - 2 years ago

Prothena Reports Third Quarter 2023 Financial Results and Business Highlights

Prothena to Report Third Quarter 2023 Financial Results on November 2

Oct 26, 2023, 4:05 PM EDT - 2 years ago

Prothena to Report Third Quarter 2023 Financial Results on November 2

Prothena prepares for potential sale - Bloomberg News

Oct 16, 2023, 11:57 AM EDT - 2 years ago

Prothena prepares for potential sale - Bloomberg News

Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise

Sep 21, 2023, 1:39 PM EDT - 2 years ago

Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise

Prothena Reports Second Quarter 2023 Financial Results and Business Highlights

Aug 3, 2023, 4:05 PM EDT - 2 years ago

Prothena Reports Second Quarter 2023 Financial Results and Business Highlights

Prothena to Report Second Quarter 2023 Financial Results on August 3

Jul 27, 2023, 4:05 PM EDT - 2 years ago

Prothena to Report Second Quarter 2023 Financial Results on August 3

Prothena: Dunn Appointment And Bristol Opt-In Boost Validation

Jul 27, 2023, 7:23 AM EDT - 2 years ago

Prothena: Dunn Appointment And Bristol Opt-In Boost Validation

Prothena Presents New Research in the Treatment of Alzheimer's Disease at Alzheimer's Association International Conference® 2023 (AAIC®)

Jul 17, 2023, 8:35 AM EDT - 2 years ago

Prothena Presents New Research in the Treatment of Alzheimer's Disease at Alzheimer's Association International Conference® 2023 (AAIC®)

Prothena to Present New Data from Alzheimer's Disease Programs at Alzheimer's Association International Conference® 2023 (AAIC®)

Jul 11, 2023, 4:05 PM EDT - 2 years ago

Prothena to Present New Data from Alzheimer's Disease Programs at Alzheimer's Association International Conference® 2023 (AAIC®)

AIIAAIIA_88
AIIAAIIA_88 Dec. 5 at 8:43 PM
$PRTA What is it with the short sellers and bears who cannot tolerate seeing this stock over $11 for a day??!! They will be kicking and crying soon enough. JMO
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Dec. 3 at 8:49 PM
https://stocktwits.com/news-articles/markets/equity/bristol-myers-stock-jumps-as-wall-street-backs-added-enrollment-in-alzheimer-s-trial/cLIXwRaRE1p This is with $PRTA drug candidate for AD. Incredible that the article does not mention $PRTA. But I know! This is why the stock is up almost 10% today.
1 · Reply
AIIAAIIA_88
AIIAAIIA_88 Dec. 3 at 2:42 PM
$PRTA Please be like CAPR soon. Very soon! 🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀🔥
0 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Dec. 2 at 7:45 PM
$PROP $PRTA $PSCE $PSCI $PSCT Undeniable Accuracy Cycle Trading Signal plugged into AI 🔥 lists 🔥 Math don't lie 🔥
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Dec. 1 at 2:52 PM
$PRTA The AD + PD winner, I am sure of. Everyone thought that this one was dead earlier this year. Not by a long shot, nope. It is still alive and kicking! You will see very soon. JMO
0 · Reply
JarvisFlow
JarvisFlow Dec. 1 at 1:17 PM
Citizens updates rating for Prothena Corp ( $PRTA ) to Market Outperform, target set at 11 → 19.
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Nov. 26 at 3:20 PM
$PRTA AD and PD are graveyards for drug candidates so far. So many Big Pharmas like NVO, JNJ, and a little biotechs like SAVA, AVXL, ALEC, ANVS, BIVI, CGTX are all failing or has failed. BMY still has PRTA’s AD drug candidate in ongoing P2 and P1, and Roche still has P3 for PRTA’s drug candidates for PD. Besides, the amyloid protein buildup is now proven to be associated with aging! For longevity, one wants to rid of the amyloids buildup! This December will be awesome! LFG!! 🔥🚀🔥🚀🔥🚀🔥🚀🔥🚀
1 · Reply
BEATOFtheMARKET
BEATOFtheMARKET Nov. 23 at 3:55 PM
$PROP $PRTA $PSCE $PSCI $PSCT 🔥
0 · Reply
buyandsold
buyandsold Nov. 22 at 2:38 AM
$PRTA this is 32% of my port, i would surely appreciate a $35 buyout on Monday
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Nov. 18 at 2:37 AM
$PRTA This biotech is already partnering with not one, not two, but three big pharma companies! BMY, NVO, RHHBY. Why chase others that keep promising partnerships that never materialize???? Beats me. LMAO
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Nov. 17 at 3:29 PM
$PRTA ANVS data are actually helping today. Tau protein in AD and PD research…. Although I do not trust ANVS, BMY will have great results with PRTA drug candidate. JMO
0 · Reply
ravi077
ravi077 Nov. 17 at 12:59 AM
$XBI 3 Biotech Stocks holding for now $VKTX $NKTR $PRTA
1 · Reply
AIIAAIIA_88
AIIAAIIA_88 Nov. 14 at 8:44 PM
$PRTA Low volume bullshit.
1 · Reply
buyandsold
buyandsold Nov. 13 at 9:51 PM
$PRTA I prefer $11 to $10 please reverse course
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Nov. 7 at 9:40 PM
$PRTA Butn the short sellers!
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 7:50 PM
HC Wainwright & Co. updates rating for Prothena Corp ( $PRTA ) to Buy, target set at 20 → 30.
0 · Reply
JarvisFlow
JarvisFlow Nov. 7 at 7:21 PM
RBC Capital updates rating for Prothena Corp ( $PRTA ) to Sector Perform, target set at 10 → 11.
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Nov. 7 at 2:38 PM
$PRTA I have not counted in the PRX005 subcutaneous injection in P1 by BMY! That will being a super-blockbuster if successful! JMO
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Nov. 6 at 11:40 PM
$PRTA Lots of good things can still happen in the remainder of 2025, such as PRX005 subcutaneous P1 data readout by BMY. A big deal, I think. Yes, sir, a big deal that nobody is paying attention to. LOL JMO
0 · Reply
buyandsold
buyandsold Nov. 1 at 12:49 AM
$PRTA i have to come to terms with the fact my 5x may take 5 years.
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Oct. 31 at 10:04 PM
$PRTA Great finish on 10/31.
0 · Reply
AIIAAIIA_88
AIIAAIIA_88 Oct. 28 at 8:50 PM
$PRTA At least, it did not finish in red... LOL
0 · Reply